Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Trizivir (AZT+3HT+Abacavir) twice dailyNCT00356616 | Germans Trias i Pujol HospitalPHASE4 | TERMINATED terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-29 |
| therapeutic autologous dendritic cellsNCT00098917 | Jonsson Comprehensive Cancer CenterPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-28 |
| autologous tumor cell vaccineNCT00098917 | Jonsson Comprehensive Cancer CenterPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-28 |
| rituximabNCT00265928 | University of VirginiaPHASE2 | TERMINATED Withdrawn for poor accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-28 |
| bortezomibNCT00265928 | University of VirginiaPHASE2 | TERMINATED Withdrawn for poor accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-28 |
| 17 Beta-estradiol (2mg/day)and (1mg/day)NCT00236301 | Assistance Publique - Hôpitaux de ParisPHASE3 | TERMINATED terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-17 |
| CLIMASTON (drug)NCT00236301 | Assistance Publique - Hôpitaux de ParisPHASE3 | TERMINATED terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-17 |
| Troxatyl™ (Cytotoxic Chemotherapeutic)NCT00104468 | SGX Pharmaceuticals, Inc.PHASE1, PHASE2 | TERMINATED Trial stopped June 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-17 |
| ThalidomideNCT00469703 | Winthrop University HospitalPHASE2 | TERMINATED Terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-16 |
| alfimepraseNCT00338585 | ARCA Biopharma, Inc.PHASE3 | TERMINATED Based upon preliminary safety and efficacy results from a similar study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2008-01-15 |
| Dexamethasone, desmopressinNCT00592566 | Mahidol UniversityPHASE2, PHASE3 | TERMINATED Numbe of eligible patients has been decreased over time. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-14 |
| LansoprazoleNCT00220909 | Temple UniversityPHASE4 | TERMINATED Recruitment slow | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-11 |
| CapecitabineNCT00176787 | University of Michigan Rogel Cancer CenterPHASE2 | TERMINATED recruitment goals met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| RituximabNCT00141700 | University of Michigan Rogel Cancer CenterPHASE2 | TERMINATED enrollment completed | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| CapecitabineNCT00148135 | University of Michigan Rogel Cancer CenterPHASE2 | TERMINATED recruitment goals met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| GemcitabineNCT00148135 | University of Michigan Rogel Cancer CenterPHASE2 | TERMINATED recruitment goals met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| CarboplatinNCT00148135 | University of Michigan Rogel Cancer CenterPHASE2 | TERMINATED recruitment goals met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| risperidoneNCT00174590 | Rush University Medical CenterPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| quetiapineNCT00174603 | Rush University Medical CenterPHASE3 | TERMINATED Unable to recruit subjects | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-10 |
| Sodium hyaluronateNCT00330135 | Daiichi SankyoPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-09 |
| ibipinabantNCT00541567 | Solvay PharmaceuticalsPHASE2, PHASE3 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2008-01-09 |
| MSI-1256F (Squalamine Lactate)NCT00094120 | Genaera CorporationPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-09 |
| FluoxentineNCT00451490 | National Taiwan University HospitalNA | WITHDRAWN This study not get the approval by the drug company | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-08 |
| AgomelatineNCT00451490 | National Taiwan University HospitalNA | WITHDRAWN This study not get the approval by the drug company | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-08 |
| Panitumumab with capecitabine and radiationNCT00346099 | NSABP Foundation IncPHASE2 | WITHDRAWN Protocol closed based on new (and as yet unpublished) information from a phase II clinical trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-01-07 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |